Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Triptorelin

Decapeptyl, Trelstar, Gonapeptyl, Pamorelin

Quick Stats
Studies 178
Trials 100
Completed OBSERVATIONAL NCT05969834

HCG Levels After Ovulation Triggering as Predictors of ICSI Outcome

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

This study aimed to assess the correlation between HCG levels after ovulation triggering and ICSI outcomes, affected by HCG formulation and dose

Detailed Description

The aims of this study are: 1. To assess the correlation between serum human chorionic gonadotropin (hCG) level after ovulation triggering and intracytoplasmic sperm injection (ICSI) outcome including: oocyte maturity and quality, good quality embryo rate, blastocyst formation rate and pregnancy rate 2. To determine if there is an association between type and dose of the trigger and ICSI outcome.

Interventions

Name: uHCG
Type: DRUG
Description: Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon)
Name: rHCG
Type: DRUG
Description: Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle)
Name: uHCG and GnRHa
Type: DRUG
Description: Final oocyte maturation will be triggered by combined SC administration of 0.1 mg of GnRHa (Decapeptyl, Triptorelin) and IM administration of 2500 IU of uHCG (Choriomon)

Primary Outcomes

Measure: Clinical pregnancy rate
TimeFrame: 6 weeks after embryo transfer
Description: Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 4-6 weeks after the ET) divided by the number of ET procedures

Trial Information

NCT ID

NCT05969834

Status

Completed

Study Type

OBSERVATIONAL

Sponsor

Mansoura University

Last Updated

December 15, 2025